MedTrace Logo

The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab

NCT05896943 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2025-03-12

No results posted yet for this study

Summary

The investigators hope that the present study will highlight new transcriptomic prognostic markers of response to Ustekinumab with the ultimate goal of individualizing treatment and making a more targeted selection of UC patients who will benefit from this biological agent.

Conditions

Interventions

DRUG

Ustekinumab

Patients with ulcerative colitis treated with ustekinumab

Sponsors & Collaborators

  • Evangelismos Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-10-31
Completion
2024-09-25

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05896943 on ClinicalTrials.gov